Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 1/20 | 1.00 |
| ▸ | KRAS | P01116 | 9/20 | 0.72 |
| ▸ | NT5E | P21589 | 1/20 | 0.72 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.68 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.63 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.63 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.63 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoaminophosphonic Acid Guanylate Ester SCHEMBL24409548 | 1.00 | TGM2 (1.00) | TGM2KRASNT5EFUT5P2RX3 | |
| Phosphoaminophosphonic Acid Guanylate Ester SCHEMBL19278241 | 1.00 | TGM2 (1.00) | TGM2KRASNT5EFUT5P2RX3 | |
| Phosphoaminophosphonic Acid Guanylate Ester SCHEMBL24591175 | 1.00 | TGM2 (1.00) | TGM2KRASNT5EFUT5P2RX3 | |
| Phosphoaminophosphonic Acid Guanylate Ester SCHEMBL20680700 | 0.99 | TGM2 (0.98) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL1894736 | 0.93 | TGM2 (0.87) | TGM2KRASNT5EFUT5 | |
| SCHEMBL24409587 | 0.93 | TGM2 (0.86) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL851357 | 0.92 | TGM2 (0.85) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL21067722 | 0.92 | TGM2 (0.85) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL18769114 | 0.92 | TGM2 (0.85) | TGM2KRASNT5EFUT5P2RX3 | |
| SCHEMBL29429843 | 0.92 | TGM2 (0.85) | TGM2KRASNT5EFUT5P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 471 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584916-B2 | Method for measuring the modulation of the activation of a G protein-coupled receptor with GTP analogues | CISBIO BIOASSAYS (FR) | 2026-03-24 | — | — | US | claimed |
| US-20260042764-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | THERAS INC (US) | 2026-02-12 | — | — | US | claimed |
| US-20260035376-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS INC (US) | 2026-02-05 | — | — | US | claimed |
| US-12522656-B2 | Anti-G-protein alpha antibody | CISBIO BIOASSAYS (FR) | 2026-01-13 | — | — | US | claimed |
| EP-4655298-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | Theras Inc. (US) | 2025-12-03 | — | — | EP | claimed |
| US-20250298017-A1 | G PROTEIN-COUPLED RECEPTOR SCREENING SYSTEMS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-09-25 | — | — | US | claimed |
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | claimed |
| US-20250188085-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | LEIDOS BIOMEDICAL RESEARCH, INC. | 2025-06-12 | — | — | US | claimed |
| EP-4565579-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | Theras, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| CN-120019052-A | Compositions and methods for inhibiting KRAS | 瑟拉斯有限公司 | 2025-05-16 | — | — | CN | claimed |
| WO-2023133183-A1 | KRAS INHIBITORS | THERAS, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| WO-2023133181-A1 | KRAS INHIBITORS | THERAS, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| US-20230135945-A1 | Method for Measuring Modulation in the Activity of a G Protein-Coupled Receptor | CISBIO ASSAYS (FR) | 2023-05-04 | — | — | US | claimed |
| US-20230091315-A1 | ANTI-G-PROTEIN ALPHA ANTIBODY | CISBIO BIOASSAYS (FR) | 2023-03-23 | — | — | US | claimed |
| WO-2023004102-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | THERAS, INC. (US) | 2023-01-26 | — | — | WO | claimed |
| EP-4097133-A1 | ANTI-G-PROTEIN ALPHA ANTIBODY | CISBIO BIOASSAYS (FR) | 2022-12-07 | — | — | EP | claimed |
| CN-115397858-A | anti-G protein alpha antibody | CISBIO生物试验公司 | 2022-11-25 | — | — | CN | claimed |
| CN-115197327-A | RNA modified chimeric protein and application thereof | 上海细胞治疗集团有限公司 | 2022-10-18 | — | — | CN | claimed |
| CN-114277072-A | KRAS protein-based nucleotide exchange method | 清华大学 | 2022-04-05 | — | — | CN | claimed |
| US-20220099669-A1 | METHOD FOR MEASURING THE MODULATION OF THE ACTIVATION OF A G PROTEIN-COUPLED RECEPTOR WITH GTP ANALOGUES | CISBIO BIOASSAYS (FR) | 2022-03-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230091315-A1 | ANTI-G-PROTEIN ALPHA ANTIBODY | GNG2, GNAI3, GNAI2 | TGM2 353/4885KRAS 72/4885NT5E 257/4885 |
| US-20260035376-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | TGM2 3050/4885KRAS 1/4885NT5E 4535/4885 |
| US-20250188085-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | TGM2 1294/4885KRAS 1/4885NT5E 3776/4885 |
| US-12584916-B2 | Method for measuring the modulation of the activation of a G protein-coupled receptor with GTP analogues | GNAI1, GNAI3, GNB1 | TGM2 584/4885KRAS 139/4885NT5E 1604/4885 |
| US-20250270206-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | TGM2 1188/4885KRAS 1/4885NT5E 3799/4885 |
| US-20260042764-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF KRAS | KRAS, NRAS, HRAS | TGM2 2416/4885KRAS 1/4885NT5E 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.